ADPT

Adaptive Biotechnologies Corporation (ADPT) Risks & Opportunities Analysis (2026)

Invetso Score: 5.2/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Profitability Cash Flow Risk

Gross margin remains strong at 75.4%, but operating margin is still negative at -12.2% and net margin at -20.7%.

Free cash flow remains negative on an enterprise-value basis, with EV/FCF at -175.4 and EV/OCF at -200.6.

Income quality is weak at 0.33, indicating earnings are not yet translating cleanly into cash.

Balance Sheet Liquidity Risk

Liquidity is solid with a current ratio of 4.79 and quick ratio of 4.68.

Cash ratio is 1.94 and working capital is positive at $332.9M, providing a cushion against near-term obligations.

Leverage remains manageable despite losses, with debt-to-equity at 2.87 and debt-to-assets at 0.64.

Valuation Risk

Valuation remains elevated at 13.7x EV/Sales and 27.4x price-to-book.

Negative earnings and cash flow keep traditional valuation multiples distorted, with P/E at -60.9 and price-to-free-cash-flow at -165.3.

The market is still pricing in meaningful future improvement despite current profitability weakness.

Operational Execution Risk

The business still converts revenue into cash inefficiently, with a cash conversion cycle of 84.0 days and operating cash flow ratio of -0.24.

SG&A remains high at 58.5% of revenue, limiting operating leverage.

R&D intensity is elevated at 28.6% of revenue, which supports product development but also pressures near-term margins.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Adaptive Biotechnologies Corporation. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →